Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.

ABSTRACT:

Background

Statins have a beneficial effect on bone mineral density (BMD) and lean mass in some studies of HIV-uninfected adults; however, this has never been investigated in the setting of HIV infection.

Design

HIV-infected individuals on stable antiretroviral therapy with a low-density lipoprotein cholesterol level of 130 mg/dl or less and evidence of heightened immune activation or inflammation were randomized to rosuvastatin 10 mg daily or placebo for 96 weeks.

Methods

This was a prespecified interim analysis at 48 weeks. Between-group and within-group differences were compared; multivariable regression models were constructed.

Results

Seventy-two individuals were randomized to statin therapy and 75 to placebo. Modest 48-week relative increases in trochante

SUBMITTER: Erlandson KM 

PROVIDER: S-EPMC4382350 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature